rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SGMT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Goldman Sachs reiterates Sagimet Biosciences stock Sell rating
      Nov 13Investing.comSGMT
      Citizens maintains Sagimet stock rating on acne pivot confidence
      Nov 13Investing.comSGMT
      Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

      Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026Completed underwritten offering of Series A Common S

      Nov 12Yahoo FinanceSGMT
      Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
      Oct 29Yahoo FinanceSGMT
      Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet

      The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Oct 23Yahoo FinanceSGMT
      Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
      Oct 23Yahoo FinanceSGMT
      Sagimet begins U.S. phase 3 trial for acne treatment denifanstat
      Oct 22Investing.comSGMT
      Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
      Oct 22Yahoo FinanceSGMT
      Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
      Oct 21Seeking AlphaSGMT
      After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
      Oct 15Yahoo FinanceSGMT
      Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
      Oct 9Yahoo FinanceSGMT
      Sagimet presents 52-week acne drug data at dermatology meeting
      Oct 9Investing.comSGMT
      Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
      Oct 9Yahoo FinanceSGMT
      Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch

      Sagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China. The company also outlined plans fo

      Oct 4Yahoo FinanceSGMT
      Guggenheim raises Sagimet stock price target on acne drug trial
      Oct 2Investing.comSGMT
      Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)

      Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailPRQRSGMT
      Sagimet closes down after acne drug denifanstat data, closing of stock offering

      Sagimet dips after Ascletis posts 52-week phase 3 open-label extension denifanstat acne data. Read more here.

      Oct 1Seeking AlphaSGMT
      Sagimet Biosciences Closes Offering of Shares, Warrants

      Sagimet Biosciences (SGMT) closed an offering of nearly 8.8 million series A common shares at $10 ap

      Oct 1Yahoo FinanceSGMT
      Sagimet closes $115 million stock offering for drug development
      Oct 1Investing.comSGMT
      Oppenheimer Adjusts Price Target on Sagimet Biosciences to $38 From $33, Maintains Outperform Rating

      Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $27.85, according t

      Oct 1Yahoo FinanceSGMT
      Cantor Fitzgerald reiterates Sagimet stock rating on acne trial data
      Oct 1Investing.comSGMT
      Citizens cuts Sagimet Biosciences stock price target on trial data
      Oct 1Investing.comSGMT
      Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
      Oct 1Yahoo FinanceSGMT
      Oppenheimer raises Sagimet stock price target on acne trial data
      Sep 30Investing.comSGMT
      Why is Sagimet Biosciences stock rallying today?
      Sep 30Investing.comSGMT
      Why Is Sagimet Biosciences Stock Trading Higher Today? - Sagimet Biosciences (NASDAQ:SGMT)

      Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.

      Sep 30BenzingaSGMT
      Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data
      Sep 30Yahoo FinanceSGMT
      Sagimet stock surges on positive acne trial data
      Sep 30Investing.comSGMT
      Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market

      Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.

      Sep 30Yahoo FinanceSGMT
      Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell

      Sagimet Biosciences (SGMT) priced an offering of about 8.8 million shares of series A common stock a

      Sep 30Yahoo FinanceSGMT
      Sagimet reports 52-week acne trial data, plans U.S. study
      Sep 30Investing.comSGMT
      Sagimet prices $115 million stock offering at $10 per share
      Sep 30Investing.comSGMT
      Sagimet reports 52-week acne drug trial results, plans U.S. study
      Sep 30Investing.comSGMT
      Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)

      Detailed price information for Neogen Corp (NEOG-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailSGMT
      H.C. Wainwright reiterates Sagimet stock rating on EADV data
      Sep 28Investing.comSGMT
      Sagimet to host event on denifanstat acne trial data Wednesday
      Sep 28Investing.comSGMT
      Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts

      On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […]

      Sep 28Yahoo FinanceSGMT
      United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR)

      United Therapeutics (UTHR) stock and Sagimet Biosciences (SGMT) stock slip as Goldman Sachs issued Sell ratings on the companies. Read more here.

      Sep 24Seeking AlphaSGMTUTHRGS
      Sagimet Biosciences at Cantor conference: acne drug push gains traction
      Sep 9Investing.comSGMT
      Barclays upgrades Sagimet stock rating on acne drug potential
      Sep 9Investing.comSGMT
      Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8

      Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.33, according t

      Sep 9Yahoo FinanceSGMT
      Cantor Fitzgerald Initiates Coverage on Sagimet Biosciences With Overweight Rating

      Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.33, according t

      Sep 9Yahoo FinanceSGMT
      Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

      FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).H.C. Wainwright 28th Annual Global Investment Conf

      Sep 2Yahoo FinanceSGMT
      Sagimet plans to start acne drug trial enrollment in Q4
      Aug 25Investing.comSGMT
      Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
      Aug 25Yahoo FinanceSGMT
      Sagimet Biosciences Says US Late-Stage Trial of Denifanstat to Treat Acne on Track for Q4 Enrollment

      Sagimet Biosciences (SGMT) said Tuesday that it expects to begin enrolling patients in Q4 for the US

      Aug 25Yahoo FinanceSGMT

      This is the newest page. Registered accounts read further back.